

Thomas E Hutson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4564013/publications.pdf>

Version: 2024-02-01

209
papers

41,842
citations

25423

59
h-index

2970

195
g-index

212
all docs

212
docs citations

212
times ranked

27068
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 1-10.	0.9	4
2	An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	0
3	The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 365-372.	1.1	5
4	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). <i>Cancer</i> , 2021, 127, 2204-2212.	2.0	32
5	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	13.9	956
6	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	0.9	20
7	A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2021, 80, 162-170.	0.9	41
8	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3725-3736.	0.8	69
9	Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 468.e1-468.e5.	0.9	7
10	Non-muscle-invasive bladder cancer: An overview of potential new treatment options. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 642-663.	0.8	30
11	Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e306-e312.	0.9	12
12	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Lancet Oncology</i> , The, 2020, 21, 95-104.	5.1	160
13	Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 2147-2164.	1.1	10
14	Advanced Non-Clear Cell Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 441-447.	1.0	1
15	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 783-785.	0.9	20
16	Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 461-468.e3.	0.9	60
17	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941.	1.1	40
18	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019, 24, 491-497.	1.9	22

#	ARTICLE	IF	CITATIONS
19	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 425-435.e4.	0.9	11
20	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. <i>European Urology</i> , 2019, 75, 929-937.	0.9	41
21	Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4517-4517.	0.8	28
22	TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4572-4572.	0.8	1
23	TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 541-541.	0.8	9
24	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 564-564.	0.8	10
25	Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 298-304.	0.9	41
26	Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. <i>European Journal of Cancer</i> , 2018, 94, 87-94.	1.3	31
27	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 757-764.	0.8	43
28	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	15.2	900
29	A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS706-TPS706.	0.8	8
30	Analysis of an online tool to explore evolving practice patterns in renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 674-674.	0.8	1
31	Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 72-76.	0.9	52
32	Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 526-533.	0.9	8
33	Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers. <i>Future Oncology</i> , 2017, 13, 1323-1332.	1.1	3
34	Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2017, 12, 333-340.	1.7	5
35	A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 2754-2760.	0.6	51
36	New treatment options for metastatic renal cell carcinoma. <i>ESMO Open</i> , 2017, 2, e000185.	2.0	60

#	ARTICLE	IF	CITATIONS
37	Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2017, 117, 478-484.	2.9	12
38	Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 168-171.	0.9	48
39	Effectiveness of Best Management Practices with Changing Climate in a Maryland Watershed. <i>Transactions of the ASABE</i> , 2017, 60, 769-782.	1.1	19
40	IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4505-4505.	0.8	55
41	A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4595-TPS4595.	0.8	5
42	Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4600-TPS4600.	0.8	2
43	A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 431-431.	0.8	59
44	Sunitinib in patients with metastatic renal cell carcinoma: Clinical outcome according to IMDC risk group.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4584-4584.	0.8	0
45	The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 113-117.	1.8	11
46	Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. <i>Future Oncology</i> , 2016, 12, 533-549.	1.1	8
47	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81.		79
48	Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. <i>ESMO Open</i> , 2016, 1, e000013.	2.0	36
49	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927.	5.1	789
50	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 406-414.	0.9	8
51	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2636-2643.	0.8	77
52	Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. <i>Lancet Oncology</i> , The, 2016, 17, e4-e5.	5.1	103
53	Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4506-4506.	0.8	1
54	Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4553-4553.	0.8	4

#	ARTICLE	IF	CITATIONS
55	The effect of geography and the availability of second-line therapy on overall survival in a one-way crossover design study in renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e16120-e16120.	0.8	1
56	Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 499-499.	0.8	10
57	Axitinib treatment among patients with mRCC in a U.S. community oncology setting: A retrospective study of 135 patients.. Journal of Clinical Oncology, 2016, 34, 569-569.	0.8	3
58	The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 113-117.	1.8	7
59	Sequential Therapy in Metastatic Renal Cell Carcinoma. Journal of Kidney Cancer and VHL, 2016, 3, 23-35.	0.2	5
60	Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients. European Journal of Cancer, 2015, 51, 1293-1302.	1.3	45
61	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncology, The, 2015, 16, 1473-1482.	5.1	762
62	A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 3420-3427.	3.2	31
63	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1814-1823.	13.9	1,004
64	First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting. Clinical Genitourinary Cancer, 2015, 13, 210-217.	0.9	23
65	Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).. Journal of Clinical Oncology, 2015, 33, 4557-4557.	0.8	5
66	Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC).. Journal of Clinical Oncology, 2015, 33, TPS4579-TPS4579.	0.8	3
67	Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. Journal of Clinical Oncology, 2015, 33, 141-141.	0.8	23
68	Development of Combination Therapy with Targeted Agents. , 2015, , 349-375.		0
69	Association of baseline IL-8 and ferritin with clinical outcome with everolimus and BNC105P in the DisrupTOR-1 trial.. Journal of Clinical Oncology, 2015, 33, 475-475.	0.8	0
70	Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 4506-4506.	0.8	7
71	Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. British Journal of Cancer, 2014, 110, 2821-2828.	2.9	89
72	Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. British Journal of Cancer, 2014, 111, 1909-1916.	2.9	150

#	ARTICLE	IF	CITATIONS
73	A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. <i>Cancer</i> , 2014, 120, 2016-2024.	2.0	19
74	Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 739-750.	1.1	69
75	Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib. <i>New England Journal of Medicine</i> , 2014, 370, 1769-1770.	13.9	251
76	Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 262-269.	0.9	9
77	Circulating proteins as potential biomarkers of sunitinib and interferon- γ efficacy in treatment-naïve patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 151-161.	1.1	52
78	A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 181-189.	1.1	83
79	Randomized Phase III Trial of Temezirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 760-767.	0.8	331
80	Dosing Patterns, Toxicity, and Outcomes in Patients Treated With First-Line Sunitinib for Advanced Renal Cell Carcinoma in Community-Based Practices. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 413-421.	0.9	15
81	Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2014, 110, 1125-1132.	2.9	76
82	Professional practice gaps and barriers to optimal care of renal cell carcinoma (RCC) among oncologists in the United States.. <i>Journal of Clinical Oncology</i> , 2014, 32, 404-404.	0.8	2
83	Practice challenges affecting optimal care as identified by US medical oncologists who treat renal cell carcinomas. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 197-204.	0.1	1
84	A phase I study of BPX-201 vaccine plus AP1903 for chemo-naïve metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3132-TPS3132.	0.8	0
85	ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4595-TPS4595.	0.8	1
86	Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2013, 369, 722-731.	13.9	1,648
87	Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1287-1294.	5.1	357
88	Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 175-181.	0.9	78
89	Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 552-562.	5.1	640
90	Everolimus vs. Temezirolimus for Advanced Renal Cell Carcinoma: Use and Use of Resources in the US Oncology Network. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 115-120.	0.9	16

#	ARTICLE	IF	CITATIONS
91	Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3791-3799.	0.8	388
92	Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2013, 108, 2470-2477.	2.9	121
93	Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1767-1774.	0.8	335
94	The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 5218-5226.	3.2	77
95	Angiopoietins and Non-VEGF Vascular Endothelial Growth Factor Antiangiogenic Targets in Advanced Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 307-310.	1.0	5
96	Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. <i>British Journal of Cancer</i> , 2013, 108, 311-318.	2.9	49
97	Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 354-354.	0.8	10
98	A phase Ib clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 358-358.	0.8	2
99	Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 79-79.	0.8	4
100	Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA348-LBA348.	0.8	10
101	Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib.. <i>Journal of Clinical Oncology</i> , 2013, 31, 364-364.	0.8	3
102	Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 397-397.	0.8	0
103	Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. <i>Annals of Oncology</i> , 2012, 23, 688-694.	0.6	39
104	Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2012, 23, 1803-1808.	0.6	120
105	Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. <i>British Journal of Cancer</i> , 2012, 106, 1475-1480.	2.9	26
106	Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon- β . <i>British Journal of Cancer</i> , 2012, 106, 1587-1590.	2.9	30
107	Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 507-512.	0.8	168
108	Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1371-1377.	0.8	254

#	ARTICLE	IF	CITATIONS
109	Survival in BRAF V600A Mutant Advanced Melanoma Treated with Vemurafenib. <i>New England Journal of Medicine</i> , 2012, 366, 707-714.	13.9	1,955
110	RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. <i>New England Journal of Medicine</i> , 2012, 366, 207-215.	13.9	978
111	Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. <i>European Journal of Cancer</i> , 2012, 48, 333-339.	1.3	117
112	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. <i>Lancet Oncology</i> , The, 2012, 13, 827-837.	5.1	240
113	Difficulty in predicting survival in metastatic renal cancer. <i>Lancet Oncology</i> , The, 2012, 13, 859-860.	5.1	9
114	Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. <i>Cancer</i> , 2012, 118, 6055-6062.	2.0	41
115	Association of Rash With Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination With Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 6-14.	0.9	28
116	Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the Community. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 1-5.	0.9	53
117	Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. <i>European Urology</i> , 2012, 61, 307-316.	0.9	52
118	Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>European Urology</i> , 2012, 61, 826-833.	0.9	59
119	Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 282-282.	0.8	6
120	Frequency of cisplatin administration in patients presenting with advanced urothelial carcinoma in the community.. <i>Journal of Clinical Oncology</i> , 2012, 30, 285-285.	0.8	3
121	Generating Youth Interest in Science Careers Through 4-H Health Science Explorations. <i>Journal of Youth Development</i> , 2012, 7, 54-60.	0.1	1
122	Management of Newly Diagnosed Metastatic Disease. , 2012, , 361-378.		0
123	Angiopoietins and Other Non-VEGF Antiangiogenic Targets in Advanced Renal Cell Carcinoma. , 2012, , 135-160.		0
124	Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group).. <i>Journal of Clinical Oncology</i> , 2012, 30, 373-373.	0.8	2
125	A hypothesis-generating exploratory analysis of efficacy and safety of abiraterone acetate (AA) in African American (Af Am) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 55-55.	0.8	0
126	Abiraterone and Increased Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1995-2005.	13.9	3,736

#	ARTICLE	IF	CITATIONS
127	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. <i>Lancet Oncology</i> , The, 2011, 12, 211-214.	5.1	261
128	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. <i>Lancet</i> , The, 2011, 378, 1931-1939.	6.3	1,663
129	Pazopanib in the treatment of renal cell carcinoma. <i>Clinical Investigation</i> , 2011, 1, 75-85.	0.0	3
130	Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. <i>BJU International</i> , 2011, 108, 1279-1283.	1.3	50
131	Sunitinib and other targeted therapies for renal cell carcinoma. <i>British Journal of Cancer</i> , 2011, 104, 741-745.	2.9	47
132	Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer. <i>Cancer</i> , 2011, 117, 752-757.	2.0	15
133	Sequential use of targeted agents in the treatment of renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 48-62.	2.0	53
134	Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2011, 22, 295-300.	0.6	136
135	Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence. <i>Oncologist</i> , 2011, 16, 14-22.	1.9	162
136	Treatment of Patients With Metastatic Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 2432-2438.	0.8	514
137	Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes. <i>Journal of Clinical Oncology</i> , 2011, 29, 2557-2564.	0.8	152
138	VEGF Pathway-Directed Therapies in Renal Carcinoma. <i>Emerging Cancer Therapeutics</i> , 2011, 2, 115-135.	0.1	0
139	Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. <i>Investigational New Drugs</i> , 2010, 28, 194-198.	1.2	11
140	Phase 3 trial of everolimus for metastatic renal cell carcinoma. <i>Cancer</i> , 2010, 116, 4256-4265.	2.0	1,039
141	Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. <i>Cancer</i> , 2010, 116, 5383-5390.	2.0	63
142	Sunitinib rechallenge in metastatic renal cell carcinoma patients. <i>Cancer</i> , 2010, 116, 5400-5406.	2.0	123
143	New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. <i>OncoTargets and Therapy</i> , 2010, 3, 147.	1.0	14
144	Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. <i>Future Oncology</i> , 2010, 6, 665-679.	1.1	26

#	ARTICLE	IF	CITATIONS
145	Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 475-480.	0.8	282
146	Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 319-324.	0.6	116
147	Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET. <i>European Journal of Cancer</i> , 2010, 46, 2432-2440.	1.3	84
148	Molecularly targeted agents for renal cell carcinoma: the next generation. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 357-60, 361-4.	0.3	7
149	Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3312-3318.	0.8	1,007
150	Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. <i>Annals of Oncology</i> , 2009, 20, 965-966.	0.6	19
151	Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1280-1289.	0.8	463
152	Novel therapeutics for metastatic renal cell carcinoma. <i>Cancer</i> , 2009, 115, 2361-2367.	2.0	19
153	Everolimus for renal cell carcinoma: predictive factors for response and future directions. <i>Medical Oncology</i> , 2009, 26, 46-53.	1.2	0
154	Systemic therapy and novel agents for metastatic castration resistant prostate cancer. <i>Update on Cancer Therapeutics</i> , 2009, 3, 133-145.	0.9	2
155	Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3584-3590.	0.8	2,020
156	Patient Selection for Phase II Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 216-219.	0.6	7
157	Abstract A11: Lower baseline levels of plasma hepatocyte growth factor, IL-6, and IL-8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib. <i>Molecular Cancer Therapeutics</i> , 2009, 8, A11-A11.	1.9	9
158	Interferons and Interleukin-2: Molecular Basis of Activity and Therapeutic Results. , 2009, , 49-78.		0
159	Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. <i>Investigational New Drugs</i> , 2008, 26, 151-158.	1.2	6
160	Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 347-354.	1.1	15
161	Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2008, 113, 1552-1558.	2.0	184
162	Axitinib for renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 741-748.	1.9	60

#	ARTICLE	IF	CITATIONS
163	Novel agents for muscle-invasive and advanced urothelial cancer. <i>BJU International</i> , 2008, 101, 937-943.	1.3	11
164	RENAL CELL CARCINOMA: WHAT DOES THE FUTURE HOLD?. <i>BJU International</i> , 2008, 102, 5-6.	1.3	3
165	Phase II Trial of Sunitinib for the Therapy of Progressive Metastatic Castration-Refractory Prostate Cancer After Previous Docetaxel Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 134-137.	0.9	9
166	Novel Antiangiogenic Agents in the Treatment of Refractory Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, S29-S36.	0.9	4
167	Novel treatment options for refractory germ cell tumors. <i>Update on Cancer Therapeutics</i> , 2008, 3, 89-96.	0.9	0
168	Development of novel agents and combinations for renal carcinoma. <i>Update on Cancer Therapeutics</i> , 2008, 3, 97-103.	0.9	0
169	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. <i>Lancet, The</i> , 2008, 372, 449-456.	6.3	2,848
170	Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 253-261.	1.9	84
171	Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3743-3748.	0.8	381
172	Sunitinib (SUTENT [®]) for the treatment of metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1723-1731.	1.1	4
173	Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. <i>Oncologist</i> , 2008, 13, 1084-1096.	1.9	198
174	Experimental therapy for advanced renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1693-1702.	1.9	8
175	Trial Design for Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 3647-3648.	0.8	2
176	Current optimal chemotherapy for advanced urothelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 51-61.	1.1	5
177	Systemic Therapy for Metastatic Renal Cell Carcinoma: Cytokines. , 2008, , 367-384.		0
178	Sunitinib (SUTENT [®]) for the treatment of metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 081017084851099.	1.1	1
179	Recent advances in the therapy of renal cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 233-242.	1.4	8
180	Management of Recurrent Testicular Germ Cell Tumors. <i>Oncologist</i> , 2007, 12, 51-61.	1.9	29

#	ARTICLE	IF	CITATIONS
181	Renal Cell Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 282-286.	1.0	21
182	Phase II trial of capecitabine and rHu-interferon- $\hat{\pm}$ -2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 46-52.	0.8	8
183	Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1193-1202.	1.1	14
184	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 115-124.	13.9	5,409
185	Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 125-134.	13.9	4,569
186	Targeted Therapy for Renal Cell Carcinoma: A New Treatment Paradigm. <i>Baylor University Medical Center Proceedings</i> , 2007, 20, 244-248.	0.2	19
187	Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. <i>Cancer</i> , 2007, 110, 2628-2639.	2.0	18
188	Phase II Study of Azacitidine to Restore Responsiveness of Prostate Cancer to Hormonal Therapy. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 457-459.	0.9	11
189	Pazopanib: A novel multitargeted tyrosine kinase inhibitor. <i>Current Oncology Reports</i> , 2007, 9, 115-119.	1.8	191
190	Evolving role of novel targeted agents in renal cell carcinoma. <i>Oncology</i> , 2007, 21, 1175-80; discussion 1184, 1187, 1190.	0.4	23
191	A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Patients with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2006, 4, 296-298.	0.9	18
192	Targeting Growth Factor and Antiangiogenic Pathways in Clear-Cell Renal Cell Carcinoma: Rationale and Ongoing Trials. <i>Clinical Genitourinary Cancer</i> , 2006, 5, S31-S39.	0.9	5
193	Hormone refractory prostate cancer: Management and advances. <i>Cancer Treatment Reviews</i> , 2006, 32, 90-100.	3.4	31
194	New Approaches in Hormone Refractory Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 196-201.	0.6	13
195	Systemic Chemotherapy for Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 34-42.	0.9	1
196	Treatment of patients with metastatic renal cell cancer. <i>Cancer</i> , 2006, 107, 2375-2383.	2.0	63
197	Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. <i>Annals of Oncology</i> , 2006, 17, 860-865.	0.6	37
198	Problems With the Randomized Discontinuation Design. <i>Journal of Clinical Oncology</i> , 2006, 24, 4669a-4670.	0.8	5

#	ARTICLE	IF	CITATIONS
199	Renal Cell Carcinoma: Diagnosis and Treatment, 1994â€“2003. Baylor University Medical Center Proceedings, 2005, 18, 337-340.	0.2	17
200	Role of 5Î±Reductase Inhibitors and Selective Estrogen Receptor Modulators as Potential Chemopreventive Agents for Prostate Cancer. Clinical Prostate Cancer, 2005, 3, 211-214.	2.1	5
201	Cytokine Therapy: A Standard of Care for Metastatic Renal Cell Carcinoma?. Clinical Genitourinary Cancer, 2005, 4, 181-186.	0.9	32
202	Alteplase for central catheter clearance: 1 mg/mL versus 2 mg/2 mL. Annals of Pharmacotherapy, 2004, 38, 351-352.	0.9	11
203	Clinical and Immunologic Effects of Subcutaneously Administered Interleukin-12 and Interferon Alfa-2b: Phase I Trial of Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma. Journal of Clinical Oncology, 2004, 22, 2891-2900.	0.8	77
204	Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma. Investigational New Drugs, 2004, 22, 277-284.	1.2	3
205	Rapid analysis of docetaxel in human plasma by tandem mass spectrometry with on-line sample extraction. Journal of Pharmaceutical and Biomedical Analysis, 2004, 36, 125-131.	1.4	34
206	Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. Cancer, 2003, 97, 170-178.	2.0	10
207	Evolving role of pegylated interferons in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2003, 3, 823-829.	1.1	20
208	Endobronchial Sarcoidosis. Journal of Bronchology, 2001, 8, 211-212.	0.2	1
209	Temporal concurrence of vasculitis and cancer: A report of 12 cases. Arthritis and Rheumatism, 2000, 13, 417-423.	6.7	78